Non-invasive Genetic Integrity Assessment of Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the genetic integrity of pluripotent stem cells in culture are invasive, time-consuming, and lack consensus on distinguishing between potentially carcinogenic mutations and benign polymorphisms, posing a risk for malignant transformation and therapeutic efficacy.
Innovation Solution
A non-invasive method using hyper-recurrent sequences as biomarkers to detect genetic abnormalities in cell culture supernatants through techniques like droplet digital-PCR, allowing for rapid assessment and isolation of stem cells free from genetic defects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive methods are used to assess genetic integrity of pluripotent stem cells, then measurement precision is improved, but productivity deteriorates and loss of time increases
Solution Approach 1:
The invention extracts and analyzes cell-free nucleic acids from culture supernatants rather than requiring direct cell manipulation. This extraction approach allows genetic integrity assessment without invasive cell processing, maintaining productivity while achieving measurement precision through analysis of circulating nucleic acid markers that reflect cellular genetic status.
Solution Approach 2:
The invention uses cell-free nucleic acids in culture supernatants as an intermediary medium to assess genetic integrity. Instead of directly analyzing cells through invasive methods, the nucleic acid markers in the supernatant serve as mediators that convey genetic information, enabling non-invasive assessment that maintains both precision and productivity.
2Measurement precision
If conventional genetic analysis methods are used, then measurement precision is improved, but device complexity and difficulty of detecting and measuring increase
Solution Approach 1:
The invention simplifies the analysis system by extracting and analyzing only cell-free nucleic acids from supernatants rather than requiring complex whole-cell genomic analysis. This extraction strategy reduces device complexity while maintaining measurement precision by focusing on specific genetic markers that indicate chromosomal abnormalities.
Solution Approach 2:
The invention applies local quality analysis by examining specific genetic regions and markers within the nucleic acids rather than analyzing the entire genome. This targeted approach to detecting genetic abnormalities in supernatants reduces the complexity of the detection system while maintaining high measurement precision for clinically relevant genetic changes.
3Reliability
If comprehensive genetic screening is performed, then reliability is improved, but loss of time and productivity deteriorate
Solution Approach 1:
The invention extracts and analyzes only the most clinically relevant genetic markers from cell-free nucleic acids in supernatants, rather than performing comprehensive whole-genome screening. This targeted extraction approach maintains reliability for detecting critical chromosomal abnormalities while significantly reducing screening time and improving productivity.
Solution Approach 2:
The invention applies partial action by performing focused genetic screening on specific high-risk genetic markers rather than comprehensive analysis of all genetic material. This partial screening approach provides sufficient reliability for therapeutic safety by detecting the most critical abnormalities, while reducing time loss and improving overall productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables quick, inexpensive, and reliable detection of genetic abnormalities, ensuring the quality and safety of pluripotent stem cells for clinical use by identifying hyper-recurrent sequences in supernatants, thereby reducing the risk of malignant transformation and improving therapeutic outcomes.
Implementation Method 1
A non-invasive method using hyper-recurrent sequences as biomarkers to detect genetic abnormalities in cell culture supernatants through techniques like droplet digital-PCR
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to a novel non-invasive method for assessing pluripotent stem cells quality in culture. More specifically, the present invention relates to a non-invasive method for assessing genetic integrity (such as the presence of CNVs) of pluripotent stem cells in culture, by assessing cell-free nucleic acids in the supernatant of the cell culture.